Fortress Biotech (FBIO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Fortress Biotech (FBIO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -38.56% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 62.15% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | 54.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.86% |
| Dec 31, 2025 | 40.15% |
| Sep 30, 2025 | 29.06% |
| Jun 30, 2025 | 37.00% |
| Mar 31, 2025 | 36.42% |
| Dec 31, 2024 | 47.91% |
| Sep 30, 2024 | 34.79% |
| Jun 30, 2024 | 33.55% |
| Mar 31, 2024 | 17.65% |
| Dec 31, 2023 | 24.47% |
| Sep 30, 2023 | 38.10% |
| Jun 30, 2023 | 1.45% |
| Mar 31, 2023 | 0.67% |
| Dec 31, 2022 | 4.27% |
| Sep 30, 2022 | 0.61% |
| Jun 30, 2022 | 5.27% |
| Mar 31, 2022 | -44.92% |
| Dec 31, 2021 | -17.81% |
| Sep 30, 2021 | -23.80% |
| Jun 30, 2021 | -6.97% |